CLNN News and Press, Clene Inc. From 11/14/25

2025-11-14 05:17:28 ET More on Clene Seeking Alpha’s Quant Rating on Clene Historical earnings data for Clene Financial information for Clene Read the full article on Seeking Alpha For further details see: Clene GAAP EPS of -$0.85 misses by...

As the U.S. Food and Drug Administration (FDA) proposed, Clene is concluding analyses of its ALS biomarker data with completion planned shortly The FDA advised Clene to request a Type C meeting to review these further ALS biomarker data analyses The Company plans to submit a New D...

RWE AG ADR (RWEOY) is expected to report $0.16 for Q3 2025 Hillenbrand Inc (HI) is expected to report $0.62 for Q4 2025 Ardent Health Inc. (ARDT) is expected to report $0.42 for Q3 2025 Quince Therapeutics Inc. (QNCX) is expected to report $-0.2 for Q3 2025 GlobalFoundries Inc. (G...

SALT LAKE CITY, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal fu...

2025-09-26 10:05:00 ET Groundbreaking research presented at the ECTRIMS 2025 conference held in Barcelona, Spain provides new insights into the ways in which menopause impacts the health implications and clinical manifestations in women who have multiple sclerosis. This study shows that...

2025-09-25 09:32:42 ET Clene (NASDAQ: CLNN) announced presentation of combined REPAIR-MS trial results at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Barcelona, showing CNM-Au8 significantly improved brain NAD+/NADH ratios, a key marke...

Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active progressive MS (primary progressive and secondary progressive MS), relapsing MS, and Parkinson’s disease patients, CN...

2025-09-16 10:05:00 ET UCLA researchers have developed a smart pen that can detect Parkinson’s during its early stages when the symptoms relied upon for the usual way to diagnose it haven’t shown up yet. Initial tests of this pen revealed an accuracy rate of 96.22%. Th...

2025-09-09 14:51:00 ET Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, recently released second ...

2025-09-05 16:37:25 ET More on Clene Seeking Alpha’s Quant Rating on Clene Historical earnings data for Clene Financial information for Clene Read the full article on Seeking Alpha For further details see: Clene files to sell 491,496 shares...